Calamos Advisors LLC Sells 118,465 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Calamos Advisors LLC reduced its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 42.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 160,324 shares of the medical equipment provider's stock after selling 118,465 shares during the quarter. Calamos Advisors LLC owned approximately 0.08% of Zimmer Biomet worth $18,145,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in ZBH. Brighton Jones LLC purchased a new stake in Zimmer Biomet in the fourth quarter worth about $204,000. Proficio Capital Partners LLC bought a new position in shares of Zimmer Biomet in the 4th quarter worth about $55,000. Fisher Asset Management LLC lifted its position in Zimmer Biomet by 7.1% during the 4th quarter. Fisher Asset Management LLC now owns 5,248 shares of the medical equipment provider's stock valued at $554,000 after acquiring an additional 348 shares during the period. SRS Capital Advisors Inc. boosted its stake in Zimmer Biomet by 146.9% during the fourth quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider's stock worth $51,000 after acquiring an additional 285 shares in the last quarter. Finally, Atria Investments Inc grew its holdings in Zimmer Biomet by 54.0% in the fourth quarter. Atria Investments Inc now owns 8,358 shares of the medical equipment provider's stock worth $883,000 after purchasing an additional 2,929 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on ZBH shares. Wells Fargo & Company cut their price target on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. BTIG Research restated a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. Canaccord Genuity Group cut their price objective on shares of Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a research report on Monday, May 12th. The Goldman Sachs Group decreased their target price on shares of Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating for the company in a report on Tuesday, May 6th. Finally, JMP Securities cut their price target on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 7th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $111.33.

Insider Buying and Selling at Zimmer Biomet

In related news, insider Sang Yi sold 1,000 shares of the business's stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total value of $95,000.00. Following the transaction, the insider directly owned 20,424 shares of the company's stock, valued at approximately $1,940,280. The trade was a 4.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.39% of the stock is currently owned by company insiders.

Zimmer Biomet Stock Performance

ZBH traded up $0.17 during trading on Friday, hitting $93.67. The company's stock had a trading volume of 927,032 shares, compared to its average volume of 1,808,334. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $116.71. The business's 50 day simple moving average is $94.04 and its 200-day simple moving average is $101.78. The company has a quick ratio of 1.46, a current ratio of 2.44 and a debt-to-equity ratio of 0.53. The firm has a market cap of $18.53 billion, a PE ratio of 20.72, a P/E/G ratio of 2.17 and a beta of 0.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The company had revenue of $1.91 billion for the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a return on equity of 12.73% and a net margin of 11.86%. Zimmer Biomet's quarterly revenue was up 1.1% compared to the same quarter last year. During the same period in the previous year, the business earned $1.94 earnings per share. As a group, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Thursday, June 26th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.02%. The ex-dividend date is Thursday, June 26th. Zimmer Biomet's dividend payout ratio (DPR) is 21.24%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.